This article originally posted 16 February, 2012 and appeared in GLP-1 Agonist, Issue 613
SPECIAL FEATURE GLP-1 TEST YOUR KNOWLEDGE, PART 3
CASE 2 – Efficacy and Benefits of GLP-1 Receptor Agonists
Paul is a 53-year-old white male who has been diagnosed with type 2 diabetes mellitus (T2DM) for about 2 years.
Advertisement
He is currently taking metformin 1000mg twice daily and glimepiride 4 mg once daily. Soon after diagnosis and beginning antihyperglycemics, Paul's glycosylated hemoglobin (A1c) showed improvement. His glycemic control worsened over subsequent years, and at a recent office visit his A1c was up to 7.8%. Paul has experienced several episodes of hypoglycemia in the last couple months. He has also continued to gain weight since diagnosis, with a current BMI of 35 kg/m2 and waist circumference of 43 inches. His most recent cholesterol panel was LDL 170 mg/dL, TG 200 mg/dL, HDL 45 mg/dL. He is currently taking simvastatin 20 mg daily.
Question 1: What is the goal A1c according to the AACE/ACE Consensus Statement on the treatment of T2DM?
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.
Entries (RSS News)
